Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

October 02, 2007; 69 (14) Articles

The incidence and significance of anti-natalizumab antibodies

Results from AFFIRM and SENTINEL

P. A. Calabresi, G. Giovannoni, C. Confavreux, S. L. Galetta, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, P. W. O'Connor, J. T. Phillips, C. H. Polman, E. -W. Radue, R. A. Rudick, W. H. Stuart, F. D. Lublin, A. Wajgt, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, M. A. Panzara
First published August 29, 2007, DOI: https://doi.org/10.1212/01.wnl.0000277457.17420.b5
P. A. Calabresi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Giovannoni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Confavreux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. L. Galetta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Havrdova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Hutchinson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Kappos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. H. Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. W. O'Connor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. T. Phillips
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. H. Polman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. -W. Radue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. A. Rudick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. H. Stuart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. D. Lublin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Wajgt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Weinstock-Guttman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. R. Wynn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Lynn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. A. Panzara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
The incidence and significance of anti-natalizumab antibodies
Results from AFFIRM and SENTINEL
P. A. Calabresi, G. Giovannoni, C. Confavreux, S. L. Galetta, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, P. W. O'Connor, J. T. Phillips, C. H. Polman, E. -W. Radue, R. A. Rudick, W. H. Stuart, F. D. Lublin, A. Wajgt, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, M. A. Panzara
Neurology Oct 2007, 69 (14) 1391-1403; DOI: 10.1212/01.wnl.0000277457.17420.b5

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
2213

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: To determine the incidence and clinical effects of antibodies that develop during treatment with natalizumab.

Methods: In two randomized, double-blind, placebo-controlled studies (natalizumab safety and efficacy in relapsing remitting multiple sclerosis [MS, AFFIRM] and safety and efficacy of natalizumab in combination with interferon β-1a [INFβ1a] in patients with relapsing remitting MS [SENTINEL]) of patients with relapsing multiple sclerosis, blood samples were obtained at baseline and every 12 weeks to determine the presence of antibodies against natalizumab. Antibodies to natalizumab were measured using an ELISA. Patients were categorized as “transiently positive” if they had detectable antibodies (≥0.5 μg/mL) at a single time point or “persistently positive” if they had antibodies at two or more time points ≥6 weeks apart.

Results: In the AFFIRM study, antibodies were detected in 57 of 625 (9%) of natalizumab-treated patients: Twenty (3%) were transiently positive and 37 (6%) were persistently positive. Persistently positive patients showed a loss of clinical efficacy as measured by disability progression (p ≤ 0.05), relapse rate (p = 0.009), and MRI (p ≤ 0.05) compared with antibody-negative patients. In transiently positive patients, full efficacy was achieved after approximately 6 months of treatment, the time when patients were becoming antibody negative. The incidence of infusion-related adverse events was significantly higher in persistently positive patients. Results of SENTINEL were similar to AFFIRM, except with regard to sustained disability progression; differences between persistently positive and antibody-negative patients were not statistically significant.

Conclusions: The incidence of persistent antibody positivity associated with natalizumab is 6%. Reduced clinical efficacy is apparent in persistently positive patients. Patients with a suboptimal clinical response or persistent infusion-related adverse events should be considered for antibody testing.

GLOSSARY: BLQ = below the limit of quantification; EDSS = Expanded Disability Status Scale; Gd+ = gadolinium enhancing; IFNβ1a = interferon β-1a; MS = multiple sclerosis; MSFC = multiple sclerosis functional composite; OD = optical density.

Footnotes

  • Editorial, see page 1386

    Received August 11, 2006. Accepted in final form April 17, 2007.

    e-Pub ahead of print on August 29, 2007, at www.neurology.org

    *These authors contributed equally.

    ‡AFFIRM and SENTINEL investigators are listed in the appendix.

    Disclosure: Disclosure information provided after the article text.

View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • APPENDIX
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder

Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu

► Watch

Related Articles

  • Neutralizing antibodies to biological therapiesA “touch of gray” vs a “black and white” story

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    The Multiple Sclerosis Functional Composite
    A clinically meaningful measure of disability
    Chris H. Polman, Richard A. Rudick et al.
    Neurology, April 26, 2010
  • Articles
    GLANCE
    Results of a phase 2, randomized, double-blind, placebo-controlled study
    A. D. Goodman, H. Rossman, A. Bar-Or et al.
    Neurology, March 02, 2009
  • Article
    Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
    Gavin Giovannoni, Jeffrey A. Cohen, Alasdair J. Coles et al.
    Neurology, October 12, 2016
  • Articles
    Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity
    Laura J. Balcer, Elliot M. Frohman et al.
    Neurology, April 26, 2010
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise